{"DataElement":{"publicId":"5222588","version":"1","preferredName":"Clinical Trial Eligibility Criteria Male Patient Contraception Agreement Indicator","preferredDefinition":"Indicator of whether or not a patient who is a sexually active man of reproductive potential who partners with women of reproductive potential, has agreed to use contraception.","longName":"MALE_CONTRCPT_IND","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"5222576","version":"1","preferredName":"Male Patient Contraception Agreement Clinical Trial Eligibility Criteria","preferredDefinition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The prevention of conception or impregnation by the use of devices or drugs or surgery._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"3383013v1.0:5222587v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"3383013","version":"1","preferredName":"Male Patient","preferredDefinition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"C20197:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Male","conceptCode":"C20197","definition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B99554C2-56F5-1119-E040-BB89AD4356C1","latestVersionIndicator":"Yes","beginDate":"2012-02-22","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-02-22","modifiedBy":"ONEDATA","dateModified":"2012-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5222587","version":"1","preferredName":"Contraception Agreement Clinical Trial Eligibility Criteria","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.:The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C37932:C25369:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30679AE0-93BC-7800-E050-BB89AD437CA8","latestVersionIndicator":"Yes","beginDate":"2016-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-13","modifiedBy":"ONEDATA","dateModified":"2016-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3066FFE0-ACF8-3F38-E050-BB89AD4326A1","latestVersionIndicator":"Yes","beginDate":"2016-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for ABTC-1501 study in Rave per request by R.Marasigan. mc 4/13/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Has the patient, who is a sex","type":"Preferred Question Text","description":"Has the patient, who is a sexually active man of reproductive potential and partners with women of reproductive potential, agreed to use contraception?","url":null,"context":"ABTC"},{"name":"Detailed Question Text","type":"Alternate Question Text","description":"If the patient is a sexually active man of reproductive potential who are partners of women with reproductive potential, has the patient agreed to use two methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 32 weeks after the last dose of study drug?","url":null,"context":"ABTC"},{"name":"ABTC 1302","type":"Alternate Question Text","description":"If the patient is a man, has the patient agreed to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to the study, for the duration of study participation, and for 4 months after completion of lapatinib administration?","url":null,"context":"ABTC"},{"name":"ABTC-1601","type":"Alternate Question Text","description":"Male patients without a vasectomy and with a partner of childbearing potential must agree to use condoms for the duration of treatment until 90 days after the last dose of study drug, and must be instructed that their female partners should use another form of contraception for the duration of treatment until 90 days after the last dose of study drug.","url":null,"context":"ABTC"},{"name":"ABTC 1603","type":"Alternate Question Text","description":"Does the sexually active male patient with female partners of reproductive potential agree to use adequate contraception prior to the study, for the duration of study participation, and at least 7 months after the last dose of study drug?","url":null,"context":"ABTC"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has the male patient agreed to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy?","url":null,"context":"COG"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does male patient with a female partner of childbearing potential agree to use a condom and ensure that an additional form of contraception is also used during treatment?","url":null,"context":"Theradex"},{"name":"ABTC 1802 Text 1","type":"Alternate Question Text","description":"Has the male patient agreed to use adequate contraception and not donate sperm from screening through 90 days after the last dose of drug?","url":null,"context":"ABTC"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has the male patient of reproductive potential agreed to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"If patient is male and of reproductive potential, has patient agreed to use an adequate method of contraception while taking DAY101 and for 120 days after the last dose?","url":null,"context":"COG"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3067ABFD-60E3-8B7D-E050-BB89AD433586","latestVersionIndicator":"Yes","beginDate":"2016-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-13","modifiedBy":"SOKKERL","dateModified":"2022-12-15","changeDescription":"Created for ABTC-1501 study in Rave per request by R.Marasigan. mc 4/13/16 03-09-2018 Fix space at end of question text DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}